INTRODUCTION {#s1}
============

Although the incidence rate of CRC decreased by approximately 3% per year during the past decade, CRC is still one of the most common cancers and the third leading cause of cancer-related death worldwide \[[@R1]\]. Despite the fact of great improvement in chemotherapy and surgical operations, the prognosis of advanced CRC is still much worse than early-stage CRC \[[@R2]\]. Therefore, for cancer prevention and early diagnosis, it is important to identify risk factors and biomarkers that are associated with disease susceptibility to screen high risk population.

The development of CRC is widely considered as a multi-step, multi-factorial process involving gene-gene and gene-environment interactions \[[@R3]\]. Previous studies have shown that lifestyle factors, such as cigarette smoking and alcohol consumption may contribute to sporadic CRC risk \[[@R4]\]. *In vivo*, these xenobiotics (e.g. nicotine and alcohol) are metabolized by xenobiotic-metabolizing enzymes including CYP1A1 superfamily, glutathione S-transferases, N-acetyltransferase, etc \[[@R5]\]. Furthermore, genetic variations of these enzymes may lead to the occurrence of CRC by metabolizing environmental insults \[[@R3]\]. In recent years, an increasing number of individual case-control studies have investigated the association of genetic variations within cytochrome P450s (CYPs) with CRC risk.

The Human Genome Project has identified 57 human cytochrome P450 enzymes, and ordered the minto 18 families and 43 subfamilies by sequence similarities \[[@R6]\]. Although most chemical carcinogens are inactive *in vivo*, they can become bio-active via CYPs. For example, benzo\[a\] pyrene can be metabolized and transformed to mutagenic benzo\[a\] pyrene diol epoxide \[[@R7], [@R8]\]. CYPs, the key of phase I enzymes, are the main enzymes in the metabolism of carcinogenic polycyclic aromatic hydrocarbons (PAHs) \[[@R9]\]. Among all researches of *CYP* involvement in procarcinogen activation, *CYP1A1s* polymorphisms of rs1048943 A \> G and rs4646903 T \> C were the most widely studied \[[@R10]\]. *CYP1A1* rs1048943 A \> G leads to amino acid change in exon 7 of *CYP1A1* from Ile to Val (nucleotides A to G) at codon 462. *CYP1A1* rs4646903 T \> C is characterized by the T to C mutation at nucleotide 3801 in the 3′-flanking region of the gene \[[@R11]\].

To date, numerous case-control studies have investigated the associations between *CYP1A1* rs1048943 A \> G, rs4646903 T \> C and CRC, but the conclusions were inconsistent. Hence, we conducted a meta-analysis to obtain a scientific conclusion.

RESULTS {#s2}
=======

Characteristics of eligible publications {#s2_1}
----------------------------------------

A total of 26 articles reporting the associations between *CYP1A1* polymorphisms and CRC risk were included in the meta-analysis. There were 20 studies (8665 cases and 9953 controls) for rs1046943 A \> G and 19 studies (6416 cases and 7551 controls) for rs4646903 T \> C. The study selection process was shown in Figure [1](#F1){ref-type="fig"} \[[@R5], [@R11]--[@R35]\].

![Flow chart of studies selection](oncotarget-07-51365-g001){#F1}

The ethnicities of the 20 publications about rs1048943 A \> G, included Asian (6 studies), Caucasian (13 studies) and mixed populations (1 study). The distribution of genotype among controls fulfilled the criteria of HWE in14 studies. There were 18 studies with high quality scores. For rs4646903 T \> C, the ethnicities of the 19 publications included Asian (7 studies) and Caucasian (12 studies). The distribution of genotype among controls fulfilled the criteria of HWE in 17 studies. There were 17 studies with high quality scores. The main characteristics of the 26 eligible studies were listed in Table [1](#T1){ref-type="table"}.

###### Characteristics of the 26 articles included in the meta-analysis

  Study            Country             Ethnicity   Source   Polymorphism   Sample size   HWE     HWE     Score
  ---------------- ------------------- ----------- -------- -------------- ------------- ------- ------- -------
  Hayashi,1992     Japan               Asian       PB       rs1048943      85/358        0.114   0.332   12
  Sivaraman,1994   Mixed               Caucasian   PB       rs1048943      43/47         0.227   0.230   11
                                                            rs4646903      43/47         0.001   0.245   11
  Frische,1999     Germany             Caucasian   PB       rs1048943      187/101       0.622   0.839   13
                                                            rs4646903      187/101       0.496   0.563   13
  Ishibe,2000      America             Caucasian   PB       rs1048943      212/221       0.018   0.057   13
                                                            rs4646903      212/221       0.247   0.428   13
  Sachse,2002      Britain             Caucasian   PB       rs1048943      490/592       0.035   0.002   11
                                                            rs4646903      490/592       0.040   0.596   14
  Ye,2002          Britain             Caucasian   PB       rs4646903      41/82         0.613   0.599   11
  Slattery,2004    America             Caucasian   PB       rs1048943      1791/2180     0.000   0.000   12
                                                            rs4646903      1805/2164     0.080   0.118   15
  Hou,2005         Mixed               Mixed       HB       rs1048943      675/679       0.117   0.478   12
  Landi,2005       Spain               Caucasian   HB       rs1048943      362/323       0.617   0.469   11
                                                            rs4646903      358/305       0.717   0.793   11
  Chen,2005        China               Asian       PB       rs4646903      139/340       0.978   0.821   13
  Little,2006      Britain             Caucasian   PB       rs1048943      251/396       0.602   0.534   14
                                                            rs4646903      232/378       0.206   0.448   14
  Bente,2006       Australia+ Poland   Caucasian   HB       rs4646903      118/100       0.039   0.637   10
  Youshida,2007    Japan               Asian       PB       rs1048943      66/121        0.910   0.800   11
                                                            rs4646903      66/121        0.244   0.623   11
  Yeh,2007         Taiwan, China       Asian       HB       rs1048943      717/729       0.000   0.280   12
  Kiss,2007        Hungary             Caucasian   HB       rs1048943      500/500       0.172   0.315   12
  Pereira, 2008    Brazil              Caucasian   PB       rs1048943      114/114       0.000   0.071   12
  Pande,2008       America             Caucasian   PB       rs1048943      120/137       0.294   0.000   10
                                                            rs4646903      120/137       0.046   0.272   13
  Zheng,2009       China               Asian       PB       rs1048943      79/110        0.056   0.031   8
                                                            rs4646903      79/110        0.479   0.272   11
  Liu,2009         China               Asian       HB       rs4646903      75/100        0.000   0.000   6
  Kobayashi,2009   Japan               Asian       HB       rs1048943      117/289       0.164   0.000   7
  Nisa,2010        Japan               Asian       PB       rs1048943      685/778       0.580   0.970   14
                                                            rs4646903      685/778       0.423   0.718   14
  Cleary,2010      Canada              Caucasian   PB       rs1048943      1174/1293     0.000   0.006   11
                                                            rs4646903      1174/1293     0.281   0.062   14
  Houlle,2011      France              Caucasian   HB       rs1048943      329/419       0.651   0.546   11
                                                            rs4646903      329/419       0.804   0.362   11
  Darazy,2011      Lebanon             Asian       PB       rs4646903      70/70         0.000   0.000   5
  Saeed,2013       Saudi Arabia        Asian       HB       rs4646903      100/79        0.374   0.726   10
  Gil,2014         Poland              Caucasian   HB       rs1048943      478/404       0.574   0.095   11

PB, population-based; HB, hospital-based; HWE, Hardy-Weinberg equilibrium.

Meta-analysis {#s2_2}
-------------

*CYP1A1* rs1048943 A \> G polymorphism {#s2_3}
--------------------------------------

The association between *CYP1A1* rs1048943 A \> G and the risk of CRC was shown in Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}. To sum up, the associations under all genetic models were statistically significant (G vs. A: OR = 1.28, 95% CI = 1.08--1.52; GG vs. AA: OR = 1.54, 95% CI = 1.25--1.91; GA vs. AA: OR = 1.26,95% CI = 1.00--1.60; GG/GA vs. AA: OR = 1.31, 95% CI = 1.05--1.64; GG vs. GA/AA: OR = 1.56, 95% CI = 1.26-1.91) ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Further stratified analysis showed the association was especially obvious in studies with population-based (PB) designs and of high quality scores. In studies of PB designs, the association was more obvious in the homozygous model (GG vs. AA: OR = 1.61, 95% CI = 1.03--2.53). In studies of high quality score, the association was more obvious using recessive model (GG vs. GA/AA: OR = 1.45, 95% CI = 1.16--1.82). Stratification analysis by ethnicity showed the association of rs1048943 A \> G and CRC were more obvious in homozygous (GG vs. AA: OR = 1.61, 95% CI = 1.04--2.47) and recessive (GG vs. GA/AA: OR = 1.59, 95% CI = 1.25-2.02) models in Asian. In Caucasian, the associations were obvious in dominant model (GA/GG vs. AA: OR=1.43, 95% CI = 1.05--1.95), heterozygous model (GA vs. AA: OR = 1.42, 95% CI = 1.04--1.96) and G allelic (G vs. A: OR = 1.33, 95% CI = 1.06--1.68). After excluding studies whose distribution of genotype in controls deviated from HWE, the association remained statistically significant (G vs. A: OR = 1.30, 95% CI = 1.05--1.61; GG vs. AA: OR = 1.51, 95% CI = 1.17--1.94; GG/GA vs. AA: OR = 1.35, 95% CI = 1.01--1.81; GG vs. GA/AA: OR = 1.52, 95% CI = 1.19--1.95). All of the results were listed in Table [2](#T2){ref-type="table"}.

###### Meta-analysis of the association between *CYP1A1* polymorphisms and CRC risk

                      G vs. A             GG vs. AA   GA vs. AA   GA/GG vs. AA        GG vs. GA/AA                                                                                                               
  ------------------- ------------------- ----------- ----------- ------------------- -------------- ------- ------------------- ------- ------- ------------------- ------- ------- ------------------- ------- -------
  rs1048943           1.28 (1.08--1.52)   0.004       0.000       1.54 (1.25--1.91)   0.000          0.228   1.26 (1.00--1.60)   0.05    0.000   1.31 (1.05--1.64)   0.018   0.000   1.56 (1.26--1.91)   0.000   0.664
   Ethnicity                                                                                                                                                                                                     
   Asian              1.14 (0.87--1.50)   0.346       0.000       1.61 (1.04--2.47)   0.031          0.049   0.93 (0.67--1.29)   0.661   0.001   1.04 (0.75--1.48)   0.809   0.000   1.59 (1.25--2.02)   0.000   0.184
   Caucasian          1.33 (1.06--1.68)   0.015       0.000       1.48 (0.95--2.32)   0.083          0.526   1.42 (1.04--1.96)   0.030   0.000   1.43 (1.05--1.95)   0.022   0.000   1.41 (0.92--2.17)   0.113   0.849
  Source of control                                                                                                                                                                                              
   PB                 1.40 (1.09--1.80)   0.009       0.000       1.61 (1.03--2.53)   0.038          0.054   1.48 (1.06--2.06)   0.021   0.000   1.52 (1.10--2.11)   0.011   0.000   1.37 (1.04--1.81)   0.024   0.373
   HB                 1.13 (0.91--1.40)   0.255       0.026       1.68 (1.22--2.33)   0.002          0.935   0.99 (0.72--1.38)   0.972   0.000   1.05 (0.79--1.41)   0.727   0.001   1.82 (1.33--2.50)   0.000   0.985
  Score                                                                                                                                                                                                          
   High               1.28 (1.08--1.52)   0.004       0.000       1.48 (1.18--1.86)   0.001          0.591   1.28 (1.01--1.62)   0.043   0.000   1.32 (1.05--1.65)   0.017   0.000   1.49 (1.19--1.86)   0.001   0.869
   Low                1.32 (0.56--3.11)   0.530       0.000       1.57 (0.42--5.93)   0.507          0.030   1.24 (0.36--4.24)   0.735   0.000   1.31 (0.41--4.22)   0.652   0.000   2.02 (1.19--3.44)   0.009   0.141
  HWE                                                                                                                                                                                                            
   Yes                1.30 (1.05--1.61)   0.015       0.000       1.51 (1.17--1.94)   0.001          0.382   1.31 (0.96--1.77)   0.088   0.000   1.35 (1.01--1.81)   0.041   0.000   1.52 (1.19--1.95)   0.001   0.719
   No                 1.25 (0.91--1.73)   0.173       0.000       1.63 (1.11--2.41)   0.013          0.113   1.19 (0.79--1.79)   0.417   0.000   1.23 (0.83--1.83)   0.297   0.000   1.63 (1.12--2.39)   0.011   0.322
                      C vs. T             CC vs. TT   CT vs. TT   CT/CC vs. TT        CC vs. CT/TT                                                                                                               
  rs4646903           1.09 (0.96--1.23)   0.186       0.001       1.11 (0.81--1.53)   0.507          0.032   1.04 (0.91--1.18)   0.594   0.034   1.07 (0.93--1.22)   0.342   0.009   1.10 (0.82--1.47)   0.530   0.053
  Ethnicity                                                                                                                                                                                                      
   Asian              1.27 (0.92--1.75)   0.140       0.000       1.17 (0.75--1.82)   0.502          0.077   1.23 (0.85--1.77)   0.267   0.016   1.32 (0.89--1.96)   0.168   0.001   1.05 (0.84--1.32)   0.666   0.279
   Caucasian          1.09 (0.92--1.28)   0.331       0.075       1.23 (0.89--1.72)   0.213          0.136   0.98 (0.88--1.10)   0.710   0.114   1.00 (0.90--1.12)   0.943   0.150   1.52 (0.81--2.85)   0.192   0.085
  Source of control                                                                                                                                                                                              
   PB                 0.99 (0.92--1.06)   0.774       0.193       1.04 (0.75--1.45)   0.826          0.058   0.98 (0.90--1.08)   0.726   0.175   0.99 (0.91--1.07)   0.745   0.235   1.05 (0.76--1.44)   0.783   0.064
   HB                 1.55 (0.92--2.61)   0.100       0.000       1.61 (0.92--2.82)   0.096          0.141   1.36 (0.86--2.14)   0.190   0.017   1.51 (0.90--2.54)   0.122   0.001   1.51 (0.87--2.62)   0.144   0.206
  Score                                                                                                                                                                                                          
   High               1.05 (0.93--1.18)   0.465       0.005       1.02 (0.74--1.41)   0.886          0.052   1.02 (0.90--1.17)   0.741   0.029   1.04 (0.91--1.18)   0.604   0.016   1.03 (0.76--1.40)   0.859   0.064
   Low                1.85 (1.19--2.87)   0.006       0.644       2.24 (1.04--4.80)   0.039          0.905   1.62 (0.80--3.28)   0.180   0.696   1.88 (1.06--3.35)   0.031   0.709   1.99 (0.95--4.16)   0.068   0.846
  HWE                                                                                                                                                                                                            
   Yes                1.05 (0.93--1.18)   0.465       0.005       1.02 (0.74--1.41)   0.886          0.052   1.02 (0.90--1.17)   0.741   0.029   1.04 (0.91--1.18)   0.604   0.016   1.03 (0.76--1.40)   0.859   0.064
   No                 1.85 (1.19--2.87)   0.006       0.644       2.24 (1.04--4.80)   0.039          0.905   1.62 (0.80--3.28)   0.180   0.696   1.88 (1.06--3.35)   0.031   0.709   1.99 (0.95--4.16)   0.068   0.846

*P* value of the *Z*-test for odds ratio test;

*P* value of the *Q*-test for heterogeneity test; PB, population based; HB, hospital based; HWE, Hardy-Weinberg equilibrium.
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*CYP1A1* rs4646903 T \> C polymorphism {#s2_4}
--------------------------------------

In the meta-analysis, the pooled analysis showed no significant association between rs4646903 T \> C and CRC risk. Further stratification analyses also found no obvious association except the subgroups of deviating from HWE and low quality score which included the same two studies showed statistical significances (C vs. T: OR = 1.85, 95% CI = 1.19--2.87; CC vs. TT: OR = 2.24, 95% CI = 1.04--4.80; CT/CC vs. TT: OR = 1.88, 95% CI = 1.06--3.35) (Table [2](#T2){ref-type="table"}).

Heterogeneity and sensitivity analysis {#s2_5}
--------------------------------------

The Chi-squared-based Q-test showed substantial heterogeneities among publications for the two polymorphisms (Table [2](#T2){ref-type="table"}). Meta-regression analysis for both polymorphisms yielded no significant difference between subgroups, except subgroups of HWE and study quality score for rs464903 T \> C. After excluding the inferior quality studies of deviate from HWE and low score, the conclusions of both polymorphisms were not change. Furthermore, we estimated the influence of single individual data on the combined ORs by consecutively omitting each study from the meta-analysis, no obvious differences were observed for both variations ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

Publication bias {#s2_6}
----------------

For rs1048943 A \> G, the shapes of funnel plots were symmetric (Figure [3](#F3){ref-type="fig"}) and Egger\'s linear regression test provided no evidence of publication bias (G vs. A: *P* = 0.185, *t* = 1.38; GG vs. AA: *P* = 0.325, *t* = 1.01; GA vs. AA: *P* = 0.132, *t* = 1.58; GG/GA vs. AA: *P* = 0.116, *t* = 1.65; GG vs. GA/AA: *P* = 0.587, *t* = 0.56). For rs4646903 T \> C the funnel plots were also symmetric and Egger\'s linear regression test provided no evidence of publication bias (CC vs. TT: *P* = 0.174, *t* = 1.42; CT vs. TT: *P* = 0.056, t = 2.05; CC vs. CT/TT: *P* = 0.234, *t* = 1.24), except two models of G allelic (C vs. T: *P* = 0.005, *t* = 3.27) and dominant model (CT/CC vs. TT: *P* = 0.013, *t* = 2.78).

![Begg\'s funnel plot of colorectal cancer risk associated with *CYP1A1* rs1048943 A \>G polymorphism (G vs. A)](oncotarget-07-51365-g003){#F3}

DISCUSSION {#s3}
==========

In this meta-analyses, we comprehensively evaluated the associations between two polymorphisms (rs1048943 A \> G and rs4646903 T \> C) and CRC risk through 26 studies. We observed that rs1048943 A \> G genetic variation was associated with increased risk of CRC. The association remained statistically significant in subgroups (Asians, Caucasians, PB, high quality score and the studies consistent with HWE). On the contrary, the association between rs4646903 T \> C and CRC risk did not reach the significance level.

CYP1A1 protein is a member of CYP superfamily and widely distributes in lung, kidney, intestine, skin, larynx, placenta, lymphocyte, brain tissues \[[@R36]\]. Because the main role of this enzyme is to metabolize environmental carcinogens, such as PAHs, heterocyclic amines, aflatoxin B1 and estrogen \[[@R37]\], variations within *CYP1A1* gene may induce the occurrence of CRC. Currently, a widely accepted paradigm for CYP1A1 enzyme mediated carcinogens activation is that CYP1A1 metabolizes polycyclic aromatic hydrocarbons to reactive epoxide intermediates, which could covalently bind to DNA and then induce tumors \[[@R38]\].

Due to the high minor allele frequency (MAF) as well as their possible involvement in an increased risk of several carcinomas \[[@R39]\], including lung cancer, colorectal cancer, breast cancer, leukemia, esophageal carcinoma and prostate cancer \[[@R40]\], *CYP1A1* rs1048943 A \> G and rs4646903 T \> C polymorphisms are more widely studied. In addition to inducing the occurrence of cancers, the polymorphisms of *CYP1A1* may also lead to other diseases, such as ulcerative colitis, colorectal adenoma, atherosclerosis, myocardial infarction and so on \[[@R41]--[@R43]\].

Partial meta-analyses on the association of *CYP1A1* polymorphisms and colorectal cancer risk showed that *CYP1A1* rs1048943 A \> G might be associated with increased risk of CRC \[[@R44], [@R45]\]. In the present study, we combined the studies to increase sample size and further validated this results. However, contradictory results were observed in a previous meta-analysis which concluded that there was no association between rs1048943 A \> G and CRC risk \[[@R46]\]. This discrepancy mainly results from sample size. We analyzed 20 studies with 8665 cases and 9953 controls while they only included two studies with 238 cases and 280 controls. For rs4646903 T \> C, previous studies showed no association with CRC risk which was consistent with us.

Compared to previous meta-analyses, the present analysis has some advantages. Firstly, we have the largest sample size with the statistic power of 92% to evaluate the associations. Secondly, 90% studies included in our meta-analyses were of high quality score. Thirdly, we conducted sensitivity analysis and found no obvious influence of a single study on the pooled ORs and 95% CIs for rs1048943 A \> G. In addition, negative result of publication bias evaluation indicated that our conclusions were unbiased. However, between-study heterogeneity existed, we should draw the conclusion with caution, subgroups analysis of rs1048943 A \> G indicated that heterogeneities may be from ethnicity, source of control or controls deviated from HWE. For rs4646903 T \> C polymorphism, substantial between-study heterogeneities may originate from ethnicity, source of control and controls deviated from HWE. Besides, for unavailable original data, we failed to analyze clinical features, such as tumor stage, age and sex, etc.

In conclusion, *CYP1A1* rs1048943 A \> G polymorphism may increase the CRC risk. However, our study still existed in some limitations, further studies with higher quality and larger sample size are necessary.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched publications from PubMed, Web of knowledge, Embase and Chinese database of China National Knowledge Infrastructure (CNKI) and VIP database with the following search items: "CYP1A1" or "Cytochrome P450 1A1" and "polymorphism" or "variant" or "SNP" and "colorectal cancer" or "colon cancer" or "rectal cancer". The languages were limited to English and Chinese. We updated the search results on January 2016 and confirmed potential relevant studies through the titles and abstracts.

Selection criteria {#s4_2}
------------------

All studies included in the meta-analysis are selected according to the following criteria: (a) case-control studies; (b) studies about the associations between *CYP1A1* rs1048943 A \> G or rs4646903 T \> C and colorectal cancer; (c) studies that contain genotype data; (d) when studies had overlapping populations, the most recent ones with the most complete data set were included. In addition, exclusion criteria were as follows: (a) overlapped articles or studies with overlapping data; (b) review articles, conference reports and dissertations.

Data extraction {#s4_3}
---------------

Two investigators (ZXR and ZML) extracted data independently from the eligible studies with the following items: the first author\'s last name, year of publication, country, ethnicity, source of controls, polymorphism type, number of cases and controls, the frequency of each genotype in cases and controls ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}), minor allele frequency (MAF) and *p*-value of Hardy Weinberg equilibrium (HWE). To get the accurate data, two investigators discussed together to reach a consensus.

Quality assessment {#s4_4}
------------------

We evaluated the quality of the included studies respectively, according to the quality assessment criteria ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) \[[@R47]--[@R50]\]. The range of quality scores are from 0 (worst) to 15 (best). Publications with quality scores \< 10 were categorized as "low quality" and those with quality scores ≥ 10 were categorized as "high quality" \[[@R51]\]. The process of scoring was listed in [Supplementary Table 2](#SD1){ref-type="supplementary-material"}.

Statistical analysis {#s4_5}
--------------------

Stata software (version 12.0; Stata Corporation, College Station, TX) was used to perform statistical analyses. We used allelic, heterozygote, homozygote, dominant and recessive as the models. The strength of associations between the *CYP1A1* rs1048943 A \> G and rs4646903 T \> C and the risk of colorectal cancer were evaluated by the pooled odds ratios (ORs) and 95% confidence intervals (CIs). We set the significance cutoff as a *p*-value of 0.05 for the pooled OR. Between-study heterogeneity was assessed using Chi-squared-based *Q*-test. If heterogeneity *P* value was lower than 0.10, we considered the heterogeneity to be significant and random-effects model was used \[[@R52]\]. Otherwise, the fixed effects model was used \[[@R53]\]. We also performed stratified analyses by ethnicity (Asian and Caucasian), control source (population-based and hospital-based), quality score of studies (low and high) and HWE. Sensitivity analyses were performed to measure the stability of the results by consecutively omitting each study from the meta-analysis (leave-one-out sensitivity analysis). Begg\'s funnel plot \[[@R54]\] and Egger\'s test \[[@R55]\] (*P* \<0.05 was considered significant) were used to evaluate the publication bias among the literatures.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s5}
==========================================
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